Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Yamazaki

Showing results (141-150 of 252) with videos related to

Pageof 26
Sort By:
Investigational New Drugs|December 22, 2010
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidinesKohei Shitara, Satoshi Yuki, Motoki Yoshida, et al.
Anticancer Research|April 4, 2021
Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib TreatmentYusuke Niisato, Toshikazu Moriwaki, Shota Fukuoka, et al.
Investigational New Drugs|May 21, 2021
Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II studyDaisuke Kotani, Takayuki Yoshino, Masahito Kotaka, et al.
Cancer Science|July 12, 2011
Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphismsTaroh Satoh, Takashi Ura, Yasuhide Yamada, et al.
The Oncologist|July 7, 2021
The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational StudyKeigo Chida, Daisuke Kotani, Toshiki Masuishi, et al.
ESMO Open|May 12, 2020
Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancerToshiki Masuishi, Hiroya Taniguchi, Takeshi Kawakami, et al.
The Oncologist|March 27, 2014
Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912Daisuke Takahari, Narikazu Boku, Junki Mizusawa, et al.
BMC Cancer|May 20, 2018
Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control studyTakeshi Kawakami, Takahiro Tsushima, Katsuhiro Omae, et al.
BMC Cancer|June 8, 2021
REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancerHiromichi Nakajima, Daisuke Kotani, Hideaki Bando, et al.
The Lancet. Oncology|August 2, 2017
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 studyYasutoshi Kuboki, Tomohiro Nishina, Eiji Shinozaki, et al.
Pageof 26

Showing results (141-150 of 252) with videos related to

Sort By:
Pageof 26
Investigational New Drugs|December 22, 2010
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidinesKohei Shitara, Satoshi Yuki, Motoki Yoshida, et al.
Anticancer Research|April 4, 2021
Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib TreatmentYusuke Niisato, Toshikazu Moriwaki, Shota Fukuoka, et al.
Investigational New Drugs|May 21, 2021
Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II studyDaisuke Kotani, Takayuki Yoshino, Masahito Kotaka, et al.
Cancer Science|July 12, 2011
Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphismsTaroh Satoh, Takashi Ura, Yasuhide Yamada, et al.
The Oncologist|July 7, 2021
The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational StudyKeigo Chida, Daisuke Kotani, Toshiki Masuishi, et al.
ESMO Open|May 12, 2020
Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancerToshiki Masuishi, Hiroya Taniguchi, Takeshi Kawakami, et al.
The Oncologist|March 27, 2014
Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912Daisuke Takahari, Narikazu Boku, Junki Mizusawa, et al.
BMC Cancer|May 20, 2018
Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control studyTakeshi Kawakami, Takahiro Tsushima, Katsuhiro Omae, et al.
BMC Cancer|June 8, 2021
REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancerHiromichi Nakajima, Daisuke Kotani, Hideaki Bando, et al.
The Lancet. Oncology|August 2, 2017
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 studyYasutoshi Kuboki, Tomohiro Nishina, Eiji Shinozaki, et al.
Pageof 26